Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by
becoming a Benzinga Pro user!
salesforce.com, inc. (NYSE: CRM) stock was trading
higher by around 5 percent early Wednesday morning in reaction to a non-GAAP first-quarter earnings beat along with a
strong second quarter and full-year 2019 sales guidance.
Aslan Pharmaceuticals ADR (NASDAQ: ASLN) was
trading higher by more than 5 percent on top of Tuesday's 14 percent gain. The clinical-stage biopharmaceutical company targeting
cancers received bullish coverage from Street analysts, including H.C. Wainwright who initiated coverage of the stock with a Buy
rating and $12 price target.
CorMedix Inc. (NYSE: CRMD) was trading higher by
around 30 percent in reaction to a Phase 3 update. The biopharmaceutical company that focuses on treating infectious and
inflammatory diseases said
it reviewed and source-verified more than 75 percent of data for the interim analysis of its Phase 3 LOCK-IT 100 study for
Neutrolin. Management expects to fully complete this work by the end of June.
Movado Group, Inc (NYSE: MOV) was trading higher by
more than 10 percent in reaction to a first-quarter earnings bet and an upward revision of its sales and EPS outlook for fiscal
2019.
Michael Kors Holdings Ltd (NYSE: KORS) was trading
lower by around 4 percent despite reporting a fiscal
fourth-quarter beat and upbeat first-quarter guidance.
Related Links:
20 Stocks Moving In
Wednesday's Pre-Market Session
Benzinga's
Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.